{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:46:21Z","timestamp":1747190781220,"version":"3.40.5"},"reference-count":26,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chinese Pharmaceutical Association-Servier Youth Hospital Pharmaceutical Innovation Research","award":["CPA-B04-ZC-2021-001","Q202118"],"award-info":[{"award-number":["CPA-B04-ZC-2021-001","Q202118"]}]},{"name":"Jiangsu Pharmaceutical Association-Hospital Pharmacy Research Project","award":["CPA-B04-ZC-2021-001","Q202118"],"award-info":[{"award-number":["CPA-B04-ZC-2021-001","Q202118"]}]},{"name":"Jiangsu Pharmaceutical Association-Hospital Pharmacy Research Project","award":["CPA-B04-ZC-2021-001","Q202118"],"award-info":[{"award-number":["CPA-B04-ZC-2021-001","Q202118"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Respiratory Journal"],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"<jats:p>Background. Both long-acting muscarinic antagonists (LAMAs) and long-acting \u03b22-agonists (LABAs) are widely used in the treatment of chronic obstructive pulmonary disease (COPD). A novel LAMA\/LABA combination of umeclidinium\/vilanterol (UMEC\/VI; 62.5\u2009\u03bcg\/25\u2009\u03bcg) is approved for chronic obstructive pulmonary disease (COPD) treatment. Objective. This study aimed to assess the efficacy and cost-effectiveness of UMEC\/VI versus tiotropium (TIO) 18\u2009\u03bcg in symptomatic patients with COPD from the perspective of the Chinese National Healthcare System. Methods. A simple analysis included three studies in the meta-analysis that compared UMEC\/VI with TIO. A Markov model was developed to estimate the cost-effectiveness of UMEC\/VI compared with TIO treatment in symptomatic patients with COPD. First, utilities, clinical efficacy, and adverse events obtained from the literature were utilized as model inputs. Costs were from Chinese average data, including local data. Costs were expressed in dollars based on 2020 prices. Then, the model outputs including drug costs, other medical costs, and total costs, and quality-adjusted life years (QALYs) were estimated. Costs and outcomes were discounted at a 5% annual rate. Furthermore, incremental cost-effective ratios (ICERs) were analyzed. Finally, the influences of changing parameters on the uncertainty of the results were assessed by means of one-way and probabilistic sensitivity analyses. Results. This study revealed that UMEC\/VI treatment had a higher rate of clinical efficacy in comparison with TIO, and the differences in the rate of adverse events between the two treatments were not significant. The results indicated that UMEC\/VI was superior to TIO, which provided an increase in QALYs (0.002) and a total cost savings of $765.67 per patient over 3 years. In the base case, the ICER of UMEC\/VI is -$397468.04\/QALY compared with TIO, suggesting that UMEC\/VI may be considered a dominant option over TIO. According to the Chinese medical system, the probability of UMEC\/VI being cost-effective was 61.6% at a willingness-to-pay (WTP) of $31554\/QALY. Sensitivity analyses confirmed that the results were robust. Conclusion. UMEC\/VI could be considered a cost-effective treatment compared with TIO in symptomatic COPD patients from the Chinese National Healthcare System perspective. These results may help decision-makers in China when making judgements on which treatments to administer.<\/jats:p>","DOI":"10.1155\/2022\/2878648","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T23:05:05Z","timestamp":1661468705000},"page":"1-12","source":"Crossref","is-referenced-by-count":2,"title":["The Efficacy and Cost-Effectiveness of Umeclidinium\/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5642-8714","authenticated-orcid":true,"given":"Yinhua","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-247X","authenticated-orcid":true,"given":"Chen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China"},{"name":"Suzhou Industrial Park Food and Drug Safety Inspection Team, Suzhou, Jiangsu 215000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-243X","authenticated-orcid":true,"given":"Yifeng","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of General Practice, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-5086","authenticated-orcid":true,"given":"Rong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3533so"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.706524"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12660"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)61097-1"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.01.006"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0936-3"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(14)70065-7"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.06.001"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.10.002"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s5237"},{"volume-title":"Chinese Pharmacoeconomics Guide","year":"2020","author":"G. E. Liu","key":"11"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523060-00008"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0909883"},{"issue":"9","key":"14","first-page":"66","article-title":"Analysis on the affordability and economic risk for using medicine to treat patients with chronic obstructive pulmonary disease in tier 3 hospitals in China","volume":"33","author":"J. Li","year":"2015","journal-title":"Chinese Health Economics"},{"key":"15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2147\/COPD.S124420","article-title":"Cost-effectiveness analysis of umeclidinium\/vilanterol for the management of patients with moderate to very severe COPD using an economic model","volume":"12","author":"M. R. Wilson","year":"2017","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"1","key":"16","first-page":"34","article-title":"The cost effectiveness analysis of indacaterol versus tiotropium in Chinese medical cost setting","volume":"138","author":"C. S. Fan","year":"2016","journal-title":"Drug Evaluation"},{"issue":"12","key":"17","first-page":"1352","article-title":"Elbasvir\/grazoprevir for patients with chronic hepatitis C virus genotype 1b infection in China: an economic evaluation","volume":"18","author":"P. Y. Chen","year":"2018","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-015-0048-6"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s94006"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.09.015"},{"key":"21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2147\/COPD.S102962","article-title":"A randomized, parallel-group study to evaluate the efficacy of umeclidinium\/vilanterol 62.5\/25 \u03bcg on health-related quality of life in patients with COPD","volume":"11","author":"T. M. Siler","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s124420"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.05.026"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1482-7"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s103335"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1038\/npjpcrm.2017.1"}],"container-title":["Canadian Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2022\/2878648.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2022\/2878648.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2022\/2878648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T23:05:21Z","timestamp":1661468721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/crj\/2022\/2878648\/"}},"subtitle":[],"editor":[{"given":"Andrea S.","family":"Melani","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":26,"alternative-id":["2878648","2878648"],"URL":"https:\/\/doi.org\/10.1155\/2022\/2878648","relation":{},"ISSN":["1916-7245","1198-2241"],"issn-type":[{"type":"electronic","value":"1916-7245"},{"type":"print","value":"1198-2241"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}